Skip to main content
Caplight Logo









ErVimmune

ErVimmune

Private
LyonHealthcare & Life Scienceshttps://ervimmune.com/

Last Round

Series A

Jan 21, 2026

Total Funding Raised

$7.3M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ErVimmune is a biotechnology company developing therapeutic vaccines and cell therapies to treat cancers that do not respond to current immunotherapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

therapeutic cancer vaccineoff-the-shelf immunotherapyhuman endogenous retrovirusesHERVcancer vaccineT-cell therapycold tumor treatmentAI-driven drug discoveryoncology biotechtarget discovery platformcancer immunotherapydrug discoveryAI in biotechcomputational biologybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ErVimmune Comparables

Compare ErVimmune with similar companies based on industry and business-model similarity.

ErVimmune comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Hervolution Therapeutics
88%
Brenus Pharma
82%
Infinitopes Precision Immunomics
73%

ErVimmune Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 21, 2026
GrantNov 1, 2023
SeedJan 9, 2023

Key People

Founding team and executive leadership

Nathalie Donne

Chief Executive Officer

Executive Team

ErVimmune Investors

Notable investors and investment history

ErVimmune investors
InvestorRounds
SPRIM Global InvestmentsSeries A
EIC AcceleratorGrant
SPRIM Global InvestmentsSeries A
BpifranceSeed
Seventure PartnersSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors increased 271% MoM, reaching 899.

  • Jan 21, 2026

    $20M raised in Series A financing.

ErVimmune Filings

Explore SEC and related filing metadata, where available.

ErVimmune filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ErVimmune's valuation, stock price, and market status.

Is ErVimmune a public or private company?

ErVimmune is a private company.

What is the current stock price of ErVimmune?

ErVimmune is a private company with no public stock price. No recent secondary market data is available.

How much is ErVimmune worth (valuation)?

Valuation information for ErVimmune is not publicly available.

Can I buy ErVimmune stock?

ErVimmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ErVimmune's last funding round?

ErVimmune's most recent funding round was Series A on January 21, 2026.

Who are the main investors in ErVimmune?

Key investors in ErVimmune include SPRIM Global Investments, EIC Accelerator, SPRIM Global Investments, Bpifrance, Seventure Partners.

Will ErVimmune IPO soon?

No public IPO plans have been announced for ErVimmune.

How can I track ErVimmune secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ErVimmune's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLyon
Employee Range18
Year Founded2019
Last FundingJan 21, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?